We report the difficulties experienced in identifying and recruiting 21 patients with ocular hypertension or primary open-angle galucoma to participate in a clinical trial of two topical beta-blockers. The case-notes of 374 consecutive patients expected to attend routine glaucoma clinics were reviewed to recruit 21 eligible patients who were willing to undergo the drug trial. Recruitment of patients to prospective drug trials may be complicated by a high proportion of exclusions due to ineligibility and also by refusal of otherwise eligible patients.
Recruitment of eligible subjects who are will ing to take part in a clinical trial is one of the major problems encountered in clinical research. 1,2 In spite of several reports from other specialties on the extent of this common problem,z-8 only limited information is avail able in the ophthalmic literature. 9 We report the difficulties experienced in identifying and recruiting patients with ocular hypertension (OH) or primary open-angle glaucoma (POAG) to participate in a double-masked, cross-over evaluation of two different beta-blockers.
Patients and methods
The proposed, comparative, evaluation of two topical beta-blockers was to be carried out in the eye department of the District General Hospital, Southport. The study patients, already well controlled on treatment with a topical ocular hypotensive agent, were required to attend the hospital on five occa sions over a period of four months with each visit lasting approximately 30 minutes. The study patients were identified and recruited in the following stages:
The case-notes of all the patiens attending the weekly glaucoma clinic were reviewed on the preceding day to identify subjects with OH and POAG who fulfilled the following condi tions for possible inclusion in the trial untreated intraocular pressure greater than 21mm HG with or without glaucomatous visual field defect and pathological cupping of the optic disc, open angle of the anterior chamber on gonioscopy and no demonstrable secondary cause of raised intraocular pressure.
Case-notes of the patients so selected were studied in detail and excluded according to the following criteria:
(1) patients younger than 18 years or older than 80 years of age (2) history or evidence of serious respir atory disorder including bronchial asthma (3) history or evidence of bradycardia (less than 55 beats per minute), heart block, ischaemic heart disease or cerebro-vas cular insufficiency (4) The patients who satisfied both the inclusion and exclusion criteria and attended the rou tine glaucoma clinic review were interviewed. The objectives of the study and the impli cations of participation were fully explained to each potential subject. Those who were unwilling to participate in the trial or were judged unsuitable were excluded from the study.
Stage III
The remainder of the potential subjects for the study underwent a comprehensive general medical examination including the cardio vascular and respiratory systems to assess their fitness for participation in the trial. A detailed medical history was also obtained. Some patients were excluded from the study at this stage due to medical problems.
Stage IV
All the willing and eligible patients were sub sequently contacted to inform them that both the investigators were available for any final clarification required before the potential subjects gave formal consent for participation in the evaluation of two ophthalmic beta-blockers. Fig. 1 Flow-chart summarizing the identification and recruitment of study patients.
Results
Reveiw of the case-notes of 374 consecutive patients expected to attend the routine glau coma clinics revealed 231 case-notes of patients with OH or POAG who satisfied the inclusion criteria. The remaining 143 case notes belonged to patients with suspect glau coma (16), narrow-angle glaucoma (34), normal tension glaucoma (16), secondary glaucoma (10) and others including post operative and casualty patients. One hundred and sixty-nine case-notes from the 231 initially identified for inclusion in the study were excluded due to the various causes listed in Table I . A single case-note was occasionally excluded for more than one reason. Forty-two patients were judged unsuitable for the study on the basis of infor mation found in their case-notes (Table I) because of visual impairment (13), poor 
*a single case-note may have been excluded due to more than one reason general health (12), lived or worked a long distance away (9) and other reasons (13).
Of the 62 patients who were eligible to pro ceed to Stage II, four failed to keep the glau coma clinic appointment. The other patients were interviewed, of whom 13 declined to participate in the study. A further 17 patients (nervous disposition 5, poor general health 5, lived or worked a long distance away 4, diffi culty in performing appalantion tonometry 2, other reasons 3) were found unsuitable for the study. The 28 remaining patients were exam ined in Stage III and of these, four were excluded due to cardiac (one patient) and res piratory (three patients) problems.
The 24 eligible and initially willing patients were subsequently contacted for definite par ticipation in the study. Three patients failed to give formal consent leaving 21 patients for inclusion in the study of two topical beta-blockers.
These 21 patients were recruited from a review of the case-notes of 374 patients expected to attend routine glaucoma clinics, a ratio of 1:18.
Discussion
Identification and recruitment of eligible sub jects who are willing to participate in a clinical trial is a major and common problem.1-9 Sev eral studies from other medical specialties3-8 have reported progressive loss of patients who were initially identified as potential subjects for inclusion in the clinical trials. The ratio of fi nal participants in the study to those who were initially identified as likely subjects varies from 1:4 in the Scottish breast conservation tria18 to 1:136 in the Systolic Hyper tension in the Edlerly Programme Study.7 In comparable ophthalmic literature Quick et al.9 reported a ratio of 1:93 (15 patients with OH or POAG were recruited from 1358 potential subjects for participation in a glau coma drug trial) which is significantly differ ent from the ratio of 1:18 experienced in the present study despite similar inclusion and exclusion criteria.
We identified potential subjects for the glaucoma drug trial by reviewing the case notes of the patients who were to attend rou tine glaucoma review clinics unlike Quick et al.9 who used an 'outpatient diagnostic index,.10 Quick et at. 9 rejected 32% of all the case-notes reviewed because these belonged to 'glaucoma suspects', a patient group which was not eligible for participation in the topical beta-blocker trial. These patients comprised only 11 % of all the case-notes we reviewed because glaucoma suspects who are normally followed at yearly intervals or more, unlike glaucoma patients who are followed at shorter intervals, are more likely to be encountered in a diagnostic index system than in a regular glaucoma clinic.
The case-notes of 176 (13% of the total) patients identified as potential subjects for the trial using the diagnostic index was not avail able to Quick et al. 9 for the purpose of review. This problem did not arise in our study as all the case-notes except one were traced and kept ready for the routine glaucoma clinic appointment. Thus glaucoma suspects and unavailable case-notes accounted for the loss of 45% of the potential subjects identifed by Quick et al. 9 for possible inclusion in the glau coma drug trial compared to 11 % in our study. We did not compare the frequency of other causes of exclusion of the original case-notes because the previous authors9 mention only one reason for excluding a case-note.
Twenty-two per cent (13) of the patients we invited personally to participate in our drug trial declined to do so. This was less than the 38% (73 patients out of the 193 invited by let ter to participate in the glaucoma drug trial) reported by Quick et al. 9 This may be because our study was of shorter duration, required fewer visits to the hospital and involved less of the patient's time. Possibly also, a direct per sonal approach by the doctor evokes patient confidence and works better than the postal approach in securing the patients' consent to undergo a clinical trial (Villada and Joyce, personal communications).
Twenty-nine per cent (17) of the inter viewed patients were found ineligible to pro ceed to the examination stage in our study compared to the 80% (96 patients out of the 120 interviewed) reported elsewhere. 9 The majority of the exclusions in that study9 after interview were due to patients on prohibited medication, presence of extensive field loss and cardio-respiratory disease and other reasons which would normally be found recorded in case-notes. It appears that either the case-notes did not contain all the relevant information or whilst unlikely, they were overlooked during the initial review of the case-notes. This may account for the high rate of rejections of potential subjects at this stage of recruitment. 9
In summary, the progressive loss of poten tial subjects for participation in a glaucoma drug trial during the various stages of identi fication and recruitment was significantly more in the previous report9 than in our study. This was due to multiple factors like the method used to identify potential subjects for inclusion in the trial, availability of the case notes for the subjects so identified, the design of the trial in terms of duration and number of patient visits required, the approach used in securing the patient's consent to undergo the drug trial and other miscellaneous factors. The impact of these factors on the progressive loss of patients during the organisation of any clinical trial is highly variable not only within the same medical speciality8,1l but also between different medical specialities. Hence, in our opinion, one should avoid esti mating the number of subjects who can be expected finally to undergo a clinical trial by adopting a specific number such as 102 or 1009 to divide the number of potential subjects. This may turn out to be too optimistic or con versely, dampen efforts to conduct trials in smaller District General Hospitals.
